Long-Term Safety of Intravenous Cardiovascular Agents in Acute Heart Failure: Results from the European Society of Cardiology Heart Failure Long-Term Registry
Alexandre Mebazaa(Marqueurs cardiovasculaires en situation de stress), Gerasimos Filippatos(National and Kapodistrian University of Athens), María G. Crespo‐Leiro(Complexo Hospitalario Universitario A Coruña), Eulàlia Roig(Hospital de Sant Pau), Ovidiu Chioncel(Carol Davila University of Medicine and Pharmacy), Lars H. Lund(Karolinska University Hospital), Justina Motiejūnaitė(Inserm), Étienne Gayat(Inserm), Petar Seferović, Aldo P. Maggioni(Health Care Foundation), Marisa Sanz Julve(Hospital Universitario Miguel Servet), Cécile Laroche(European Society of Cardiology), Frank Ruschitzka(Kantonsspital St. Gallen), Veli‐Pekka Harjola(Polskie Towarzystwo Gastroenterologii), Eiichi Akiyama(Kumamoto University)
Cited by 113
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
|European Journal of Heart Failure|2008|3.5k